Showing results (41-50 of 88) with videos related to
Sort By:
Pageof 9
Blood|April 7, 2021
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study resultsRanjana H Advani, Alison J Moskowitz, Nancy L Bartlett, et al.British Journal of Haematology|March 14, 2012
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphomaMyron S Czuczman, Georg Hess, Ole V Gadeberg, et al.Blood Advances|February 19, 2021
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFINPeter M Voorhees, Cesar Rodriguez, Brandi Reeves, et al.Cancer|February 27, 2010
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemiaNeil E Kay, Wenting Wu, Brian Kabat, et al.The Oncologist|April 24, 2022
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple MyelomaAndrzej J Jakubowiak, Shaji Kumar, Rohan Medhekar, et al.British Journal of Haematology|December 18, 2009
Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive diseaseJennifer A Woyach, Nyla A Heerema, John Zhao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Susan O'Brien, Ian W Flinn, et al.Leukemia & Lymphoma|March 6, 2009
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphomaKristie A Blum, Mehdi Hamadani, Gary S Phillips, et al.British Journal of Haematology|March 5, 2019
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA studyHabte Yimer, Jason Melear, Edward Faber, et al.Pageof 9